S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 64,417.86 +0.81%
Next Bullish Trade
Sign in
NVO

NVO NYQ · NVO

$50.32 -1.16 (-2.25%)
Extended · +1.41σ Grade C

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · NVO

Momentum reads · latest daily bar
Last
$50.32
-1.16 (-2.25%)
Mkt cap
$222.6B
Healthcare
RSI(14)
62.6
neutral
Stochastic %K
82.7
overbought
MFI(14)
55.0
neutral
ADX(14)
27.1
trending

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $96.8B $48.6B $59.6B $12.0B 50.2% 61.6%
2025-12-31 $79.1B $26.9B $31.7B $-36.2B 34.0% 40.1%
2025-09-30 $75.0B $20.0B $23.7B $30.7B 26.7% 31.6%
2025-06-30 $76.9B $26.5B $33.4B $24.4B 34.5% 43.5%
2025-03-31 $78.1B $29.0B $38.8B $10.1B 37.2% 49.7%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare NVO vs peers

Line NVO up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing NVO LLY× UNH×
Verdict
Weighted score 0-100 across 3 tickers · best in green
#3
NVO
score 41.6
5/5 inputs
Growth score zero due to 67% EPS growth gets only 24 points, dragging total below despite 93 quality.
value 67growth 24quality 93momentum 25sentiment 0
#1
LLY
score 61.0
5/5 inputs
Growth dominates with perfect 100 score from 56% revenue and 170% EPS growth, outweighing expensive 42x PE.
value 25growth 100quality 74momentum 53sentiment 54
#2
UNH
score 50.3
5/5 inputs
Growth crashes to zero with only 0.4% revenue growth, offsetting strong 73 momentum and 100 sentiment scores.
value 73growth 0quality 17momentum 73sentiment 100
NVO
NVO
$50.32
-2.25%
Snapshot
Price 50.32
Day % -2.25
1M % 15.55
3M % 22.94
YTD % -3.95
Market cap 222607147008.0
ADV ($) 704227238.369072
Beta 0.36
OdysseyHQ zone
Current zone Extended
Dist 21-EMA % 3.86
Dist ATR (σ) 1.41
OdysseyHQ grade C
Confluence 3
Valuation
P/E (ttm) 12.067146
P/E (fwd) 14.920657
P/S 0.67909443
EV/EBITDA 2.003
P/B 7.20427
FCF yield -0.0541
PEG 3.72
Growth
Revenue yoy 0.24
EPS yoy 0.671
FCF yoy
Revenue trend 8Q
Quality
Gross margin 0.83195996
Operating margin 0.61574
Net margin 0.37205002
ROE 0.71402
ROA 0.19249001
Debt / Equity 0.72
Interest cov. 32.03
Technicals
RSI(14) 62.6
MACD signal bull
vs 50-DMA 9.2
vs 200-DMA 6.18
vs 52w high -29.92
HV-30 34.9
Sentiment
Analyst rec 2.42857
Target upside -5.47
Insider buy-sell 90d
Risk
Short interest 0.88
Days to cover 2.05
Next earnings 2026-08-05
Full NVO dashboard →
LLY
LLY
$1179.11
+0.85%
Snapshot
Price 1179.11
Day % 0.85
1M % 5.04
3M % 30.43
YTD % 9.14
Market cap 1051461156864.0
ADV ($) 3829619530.3234863
Beta 0.506
OdysseyHQ zone
Current zone Neutral
Dist 21-EMA % 0.95
Dist ATR (σ) 0.29
OdysseyHQ grade
Confluence 1
Valuation
P/E (ttm) 41.842087
P/E (fwd) 26.255041
P/S 14.553297
EV/EBITDA 30.086
P/B 33.768936
FCF yield 0.0087
PEG 1.58
Growth
Revenue yoy 0.555
EPS yoy 1.699
FCF yoy
Revenue trend 8Q
Quality
Gross margin 0.82832
Operating margin 0.49386
Net margin 0.34986
ROE 1.07459
ROA 0.20739001
Debt / Equity 1.39
Interest cov.
Technicals
RSI(14) 54.8
MACD signal neutral
vs 50-DMA 6.28
vs 200-DMA 17.06
vs 52w high -5.63
HV-30 32.5
Sentiment
Analyst rec 1.75862
Target upside 7.74
Insider buy-sell 90d 9
Risk
Short interest 1.05
Days to cover 2.74
Next earnings 2026-08-05
Full LLY dashboard →
UNH
UnitedHealth Group Incorporated
$426.09
+0.64%
Snapshot
Price 426.09
Day % 0.64
1M % 4.52
3M % 34.67
YTD % 26.66
Market cap 386951249920.0
ADV ($) 3118003879.2817383
Beta 0.633
OdysseyHQ zone
Current zone Neutral
Dist 21-EMA % 1.78
Dist ATR (σ) 0.6
OdysseyHQ grade C
Confluence 3
Valuation
P/E (ttm) 32.060947
P/E (fwd) 19.240608
P/S 0.85964525
EV/EBITDA 17.696
P/B 3.9526708
FCF yield 0.0588
PEG 1.42
Growth
Revenue yoy 0.004
EPS yoy 0.615
FCF yoy
Revenue trend 8Q
Quality
Gross margin 0.19514
Operating margin 0.071329996
Net margin 0.03137
ROE 0.14152999
ROA 0.04382
Debt / Equity 0.69
Interest cov. 4.67
Technicals
RSI(14) 57.9
MACD signal neutral
vs 50-DMA 5.76
vs 200-DMA 24.8
vs 52w high -7.7
HV-30 26.9
Sentiment
Analyst rec 1.59259
Target upside 10.69
Insider buy-sell 90d 23
Risk
Short interest 2.26
Days to cover 2.55
Next earnings 2026-07-16
Full UNH dashboard →

Earnings replay · last 20 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

DateEPS actual EPS estSurprise Next-day
2026-05-05 6.63 6.96 -4.8% +2.0%
2026-02-03 6.04 5.90 +2.3% -6.2%
2025-11-05 4.50 4.24 +6.0% -4.0%
2025-08-06 5.96 6.00 -0.7% +7.5%
2025-05-07 6.53 6.07 +7.5% -4.0%
2025-02-04 6.34 5.97 +6.2% +3.8%
2024-11-06 6.12 5.92 +3.4% +2.1%
2024-08-07 4.49 4.91 -8.6% +7.5%
2024-05-02 5.68 5.42 +4.9% -0.8%
2024-01-31 4.91 4.45 +10.3% +0.9%
2023-11-02 5.00 4.71 +6.2% -2.7%
2023-08-09 4.32 4.50 -4.0% -2.9%
2023-05-04 4.39 4.02 +9.1% +1.8%
2023-02-01 3.01 3.13 -3.8% -4.8%
2022-11-02 3.17 3.12 +1.7% +0.6%
2022-08-03 2.93 3.03 -3.4% +4.6%
2022-04-29 3.11 2.89 +7.5% -0.1%
2022-02-01 2.38 2.36 +1.0% +3.9%
2021-11-03 2.64 2.55 +3.2% +0.2%
2021-08-04 2.63 2.38 +10.4% +5.0%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
NVO $223B 12.1 14.9 0.7 2.0 7.2 83.2% 24.0% 67.1% -5.41%
LLY $1,051B 41.8 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 32.1 19.2 0.9 17.7 4.0 19.5% 0.4% 61.5% 5.88%
JNJ $609B 29.3 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0%
MRK $315B 36.0 13.2 4.8 12.1 6.9 76.7% 4.9% 4.46%
ABBV $450B 124.8 15.6 7.2 17.2 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.6 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.2 19.5 4.4 21.1 3.8 40.9% 6.2% 11.3% 2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 3.73%

HolderShares% out
Dodge & Cox Inc. 19,333,750 0.57%
LOOMIS SAYLES & CO L P 17,017,315 0.50%
Franklin Resources, Inc. 16,083,479 0.47%
Capital International Investors 11,795,850 0.35%
Susquehanna International Group, LLP 11,106,111 0.33%
Price (T.Rowe) Associates Inc 11,060,680 0.33%
Morgan Stanley 10,869,200 0.32%
Bank of America Corporation 10,769,699 0.32%
Fisher Asset Management, LLC 9,021,103 0.27%
Folketrygdfondet 9,080,820 0.27%

Insider activity · 90d

No insider trades for NVO in last 90d.

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$40.006428
Mean
$47.565586
High
$63.152065
Analysts
12
Recommendation distribution · period 2026-07-01
5
8
22
1
1
Revision trend (2026-04-01 → 2026-07-01): net 10 → 11 +1 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

No filings available.

About NVO

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Options picks · NVO

ITM + OTM ideas from the latest scan

Loading…

Congress trades · NVO

STOCK Act disclosures

Loading…

SEC filings & insiders · NVO

EDGAR · live

Loading…

Holders · NVO

Institutions & insider activity

Loading…